Recent Categories
- ADD/ADHD-Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder
- ALS-Amyotrophic lateral sclerosis
- Alzheimer's Disease
- Anorexia
- Anxiety Disorders (including Panic Attacks and Phobias)
- Arthritis/Inflammation
- Asthma
- Autism
- Blood Pressure (Hypertension)
- Brain Cancer
- Breast Cancer
- Broken Bones
- Cancer
- Chemotherapy Side Effects
- Huntington Disease
- Leukemia
- Liver Cancer
- Lung Cancer
- Medical Conditions
- Osteoarthritis
- Osteoporosis
- Parkinson's Disease
- Prostate
- Stomach Cancer
Recent Posts
Post Archive
Catogery Tags
Connect With Us
-
Brain Cancer Research-2011 Jan
In 2011, A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma.Tumors were induced in nude mice BACKGROUND: The present work was therefore undertaken to study the potential synergic antitumoral action of TMZ (the benchmark agent for the management of GBM) and THC and CBD. Mice were assigned randomly to various groups and injected peritumorally for…
-
Brain Cancer Research-2004 Mar
In 2004, Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines BACKGROUND: study to evaluate the in vitro antiproliferative ability of cannabidiol (CBD), a nonpsychoactive cannabinoid compound, on U87 and U373 human glioma cell lines. You can read the full article here => http://jpet.aspetjournals.org/content/308/3/838
-
Brain Cancer Research-2001 Sep
In 2001, Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity BACKGROUND: We show in a longitudinal magnetic resonance imaging study that Δ9-tetrahydrocannabinol (Δ9-THC), the main active compound in marijuana, reduces neuronal injury in neonatal rats injected intracerebrally with the Na+/K+-ATPase inhibitor ouabain to elicit excitotoxicity. You can read the full article here…
-
Brain Cancer Research-2001 Aug
In 2001, Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor BACKGROUND: Here we show that local administration of the selective CB2 agonist JWH-133 at 50 μg/day to Rag-2−/− mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells. Cannabinoid receptor expression was subsequently examined in biopsies from human astrocytomas You can…
-
Brain Cancer Study-2006 Jul
in 2006, A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme BACKGROUND: Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. You can read the full article here => https://www.nature.com/articles/6603236
